KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Medtronic (MDT) EBITDA Margin (2016 - 2026)

Medtronic's EBITDA Margin history spans 13 years, with the latest figure at 16.24% for Q1 2026.

  • On a quarterly basis, EBITDA Margin fell 361.0% to 16.24% in Q1 2026 year-over-year; TTM through Jan 2026 was 17.0%, a 21.0% increase, with the full-year FY2025 number at 17.76%, up 186.0% from a year prior.
  • EBITDA Margin hit 16.24% in Q1 2026 for Medtronic, down from 18.81% in the prior quarter.
  • Over the last five years, EBITDA Margin for MDT hit a ceiling of 21.37% in Q1 2022 and a floor of 12.26% in Q2 2024.
  • Historically, EBITDA Margin has averaged 17.58% across 5 years, with a median of 18.01% in 2023.
  • Biggest five-year swings in EBITDA Margin: soared 495bps in 2022 and later plummeted -605bps in 2024.
  • Tracing MDT's EBITDA Margin over 5 years: stood at 18.51% in 2022, then decreased by -9bps to 16.78% in 2023, then rose by 13bps to 18.98% in 2024, then dropped by -1bps to 18.81% in 2025, then dropped by -14bps to 16.24% in 2026.
  • Business Quant data shows EBITDA Margin for MDT at 16.24% in Q1 2026, 18.81% in Q4 2025, and 16.85% in Q3 2025.